Dare Bioscience, Inc.

DARE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Revenue $766.0K $80.0K $6.0K $625.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $6.4M $984.7K $72.7K $25.9M $11.8M $9.7M $15.8M
SG&A Expense $4.7M $2.7M $157.9K $11.2M $8.6M $6.2M $6.4M
Operating Income $-16.9M $-11.2M $-630.6K
Operating Margin -82.3%
Interest Expense $322.6K $42.1K $2.4M $1.1M $1.5M $567.0K
Pretax Income $-16.8M $-11.5M $-673.0K
Income Tax Expense $3.2K $0
Net Income $-16.7M $-11.5M $-672.7K $-39.6M $-23.3M $-17.1M $-22.1M
Net Margin -87.8% -29,177.5% -285,716.7% -3,536.2%
EPS (Basic) $-0.79 $1.78 $-0.10 $-0.20 $-0.20 $-3.13 $-4.55
EPS (Diluted) $-0.79 $1.78 $-0.10 $-0.20 $-0.20 $-3.13 $-4.55
Shares Outstanding (Basic) 22.8M 6.5M 6.7M 218.8M 161.0M 6.3M
Shares Outstanding (Diluted) 22.8M 6.5M 6.7M 218.8M 161.0M 6.3M
Dividends Per Share
← Newer Page 2 of 2 Older →